Eintrag weiter verarbeiten
Review article: current perspectives on hypergastrinaemia and enterochromaffin‐like‐cell hyperplasia
Gespeichert in:
| Zeitschriftentitel: | Alimentary Pharmacology & Therapeutics |
|---|---|
| Personen und Körperschaften: | |
| In: | Alimentary Pharmacology & Therapeutics, 13, 1999, s5, S. 5-10 |
| Format: | E-Article |
| Sprache: | Englisch |
| veröffentlicht: |
Wiley
|
| Schlagwörter: |
| author_facet |
Robinson Robinson |
|---|---|
| author |
Robinson |
| spellingShingle |
Robinson Alimentary Pharmacology & Therapeutics Review article: current perspectives on hypergastrinaemia and enterochromaffin‐like‐cell hyperplasia Pharmacology (medical) Gastroenterology Hepatology |
| author_sort |
robinson |
| spelling |
Robinson 0269-2813 1365-2036 Wiley Pharmacology (medical) Gastroenterology Hepatology http://dx.doi.org/10.1046/j.1365-2036.1999.00033.x <jats:p>Rabeprazole, a new benzimidazole proton pump inhibitor (PPI), is among a class of agents known to be very potent inhibitors of gastric acid secretion. PPIs inhibit hydrogen‐potassium adenosine triphosphatase activity on the luminal surface of the parietal cell, effectively blocking the final common pathway for gastric acid secretion. Raising gastric pH stimulates the production of gastrin by G cells in the antrum of the stomach, which can lead to enterochromaffin‐like (ECL)‐cell hyperplasia. In the past, these changes have been viewed with concern, particularly in the light of studies in rats indicating that hypergastrinaemia and ECL‐cell hyperplasia induce gastric carcinoid tumour formation. All available clinical data indicate that long‐term PPI use does not lead to carcinoid tumour formation in humans. In fact, both serum gastrin elevation and ECL‐cell hyperplasia are now generally viewed as normal physiological responses to gastric acid suppression. Serum gastrin concentrations, in particular, correlate well with gastric acid suppression, which has led to the use of gastrin response by some investigators as a surrogate marker of antisecretory effectiveness. Long‐term tolerability data indicate that PPIs have a favourable side‐effect profile. Data obtained from patients receiving acute or long‐term maintenance rabeprazole therapy support this conclusion. Furthermore, neither animal nor human data obtained with rabeprazole suggest a significant risk for neoplastic changes secondary to hypergastrinaemia.</jats:p> Review article: current perspectives on hypergastrinaemia and enterochromaffin‐like‐cell hyperplasia Alimentary Pharmacology & Therapeutics |
| doi_str_mv |
10.1046/j.1365-2036.1999.00033.x |
| facet_avail |
Online Free |
| finc_class_facet |
Chemie und Pharmazie Medizin |
| format |
ElectronicArticle |
| fullrecord |
blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTA0Ni9qLjEzNjUtMjAzNi4xOTk5LjAwMDMzLng |
| id |
ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTA0Ni9qLjEzNjUtMjAzNi4xOTk5LjAwMDMzLng |
| institution |
DE-D275 DE-Bn3 DE-Brt1 DE-Zwi2 DE-D161 DE-Gla1 DE-Zi4 DE-15 DE-Pl11 DE-Rs1 DE-105 DE-14 DE-Ch1 DE-L229 |
| imprint |
Wiley, 1999 |
| imprint_str_mv |
Wiley, 1999 |
| issn |
0269-2813 1365-2036 |
| issn_str_mv |
0269-2813 1365-2036 |
| language |
English |
| mega_collection |
Wiley (CrossRef) |
| match_str |
1999reviewarticlecurrentperspectivesonhypergastrinaemiaandenterochromaffinlikecellhyperplasia |
| publishDateSort |
1999 |
| publisher |
Wiley |
| recordtype |
ai |
| record_format |
ai |
| series |
Alimentary Pharmacology & Therapeutics |
| source_id |
49 |
| title |
Review article: current perspectives on hypergastrinaemia and enterochromaffin‐like‐cell hyperplasia |
| title_unstemmed |
Review article: current perspectives on hypergastrinaemia and enterochromaffin‐like‐cell hyperplasia |
| title_full |
Review article: current perspectives on hypergastrinaemia and enterochromaffin‐like‐cell hyperplasia |
| title_fullStr |
Review article: current perspectives on hypergastrinaemia and enterochromaffin‐like‐cell hyperplasia |
| title_full_unstemmed |
Review article: current perspectives on hypergastrinaemia and enterochromaffin‐like‐cell hyperplasia |
| title_short |
Review article: current perspectives on hypergastrinaemia and enterochromaffin‐like‐cell hyperplasia |
| title_sort |
review article: current perspectives on hypergastrinaemia and enterochromaffin‐like‐cell hyperplasia |
| topic |
Pharmacology (medical) Gastroenterology Hepatology |
| url |
http://dx.doi.org/10.1046/j.1365-2036.1999.00033.x |
| publishDate |
1999 |
| physical |
5-10 |
| description |
<jats:p>Rabeprazole, a new benzimidazole proton pump inhibitor (PPI), is among a class of agents known to be very potent inhibitors of gastric acid secretion. PPIs inhibit hydrogen‐potassium adenosine triphosphatase activity on the luminal surface of the parietal cell, effectively blocking the final common pathway for gastric acid secretion. Raising gastric pH stimulates the production of gastrin by G cells in the antrum of the stomach, which can lead to enterochromaffin‐like (ECL)‐cell hyperplasia. In the past, these changes have been viewed with concern, particularly in the light of studies in rats indicating that hypergastrinaemia and ECL‐cell hyperplasia induce gastric carcinoid tumour formation. All available clinical data indicate that long‐term PPI use does not lead to carcinoid tumour formation in humans. In fact, both serum gastrin elevation and ECL‐cell hyperplasia are now generally viewed as normal physiological responses to gastric acid suppression. Serum gastrin concentrations, in particular, correlate well with gastric acid suppression, which has led to the use of gastrin response by some investigators as a surrogate marker of antisecretory effectiveness. Long‐term tolerability data indicate that PPIs have a favourable side‐effect profile. Data obtained from patients receiving acute or long‐term maintenance rabeprazole therapy support this conclusion. Furthermore, neither animal nor human data obtained with rabeprazole suggest a significant risk for neoplastic changes secondary to hypergastrinaemia.</jats:p> |
| container_issue |
s5 |
| container_start_page |
5 |
| container_title |
Alimentary Pharmacology & Therapeutics |
| container_volume |
13 |
| format_de105 |
Article, E-Article |
| format_de14 |
Article, E-Article |
| format_de15 |
Article, E-Article |
| format_de520 |
Article, E-Article |
| format_de540 |
Article, E-Article |
| format_dech1 |
Article, E-Article |
| format_ded117 |
Article, E-Article |
| format_degla1 |
E-Article |
| format_del152 |
Buch |
| format_del189 |
Article, E-Article |
| format_dezi4 |
Article |
| format_dezwi2 |
Article, E-Article |
| format_finc |
Article, E-Article |
| format_nrw |
Article, E-Article |
| _version_ |
1792343627243978754 |
| geogr_code |
not assigned |
| last_indexed |
2024-03-01T16:54:43.108Z |
| geogr_code_person |
not assigned |
| openURL |
url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=Review+article%3A+current+perspectives+on+hypergastrinaemia+and+enterochromaffin%E2%80%90like%E2%80%90cell+hyperplasia&rft.date=1999-10-01&genre=article&issn=1365-2036&volume=13&issue=s5&spage=5&epage=10&pages=5-10&jtitle=Alimentary+Pharmacology+%26+Therapeutics&atitle=Review+article%3A+current+perspectives+on+hypergastrinaemia+and+enterochromaffin%E2%80%90like%E2%80%90cell+hyperplasia&aulast=Robinson&rft_id=info%3Adoi%2F10.1046%2Fj.1365-2036.1999.00033.x&rft.language%5B0%5D=eng |
| SOLR | |
| _version_ | 1792343627243978754 |
| author | Robinson |
| author_facet | Robinson, Robinson |
| author_sort | robinson |
| container_issue | s5 |
| container_start_page | 5 |
| container_title | Alimentary Pharmacology & Therapeutics |
| container_volume | 13 |
| description | <jats:p>Rabeprazole, a new benzimidazole proton pump inhibitor (PPI), is among a class of agents known to be very potent inhibitors of gastric acid secretion. PPIs inhibit hydrogen‐potassium adenosine triphosphatase activity on the luminal surface of the parietal cell, effectively blocking the final common pathway for gastric acid secretion. Raising gastric pH stimulates the production of gastrin by G cells in the antrum of the stomach, which can lead to enterochromaffin‐like (ECL)‐cell hyperplasia. In the past, these changes have been viewed with concern, particularly in the light of studies in rats indicating that hypergastrinaemia and ECL‐cell hyperplasia induce gastric carcinoid tumour formation. All available clinical data indicate that long‐term PPI use does not lead to carcinoid tumour formation in humans. In fact, both serum gastrin elevation and ECL‐cell hyperplasia are now generally viewed as normal physiological responses to gastric acid suppression. Serum gastrin concentrations, in particular, correlate well with gastric acid suppression, which has led to the use of gastrin response by some investigators as a surrogate marker of antisecretory effectiveness. Long‐term tolerability data indicate that PPIs have a favourable side‐effect profile. Data obtained from patients receiving acute or long‐term maintenance rabeprazole therapy support this conclusion. Furthermore, neither animal nor human data obtained with rabeprazole suggest a significant risk for neoplastic changes secondary to hypergastrinaemia.</jats:p> |
| doi_str_mv | 10.1046/j.1365-2036.1999.00033.x |
| facet_avail | Online, Free |
| finc_class_facet | Chemie und Pharmazie, Medizin |
| format | ElectronicArticle |
| format_de105 | Article, E-Article |
| format_de14 | Article, E-Article |
| format_de15 | Article, E-Article |
| format_de520 | Article, E-Article |
| format_de540 | Article, E-Article |
| format_dech1 | Article, E-Article |
| format_ded117 | Article, E-Article |
| format_degla1 | E-Article |
| format_del152 | Buch |
| format_del189 | Article, E-Article |
| format_dezi4 | Article |
| format_dezwi2 | Article, E-Article |
| format_finc | Article, E-Article |
| format_nrw | Article, E-Article |
| geogr_code | not assigned |
| geogr_code_person | not assigned |
| id | ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTA0Ni9qLjEzNjUtMjAzNi4xOTk5LjAwMDMzLng |
| imprint | Wiley, 1999 |
| imprint_str_mv | Wiley, 1999 |
| institution | DE-D275, DE-Bn3, DE-Brt1, DE-Zwi2, DE-D161, DE-Gla1, DE-Zi4, DE-15, DE-Pl11, DE-Rs1, DE-105, DE-14, DE-Ch1, DE-L229 |
| issn | 0269-2813, 1365-2036 |
| issn_str_mv | 0269-2813, 1365-2036 |
| language | English |
| last_indexed | 2024-03-01T16:54:43.108Z |
| match_str | 1999reviewarticlecurrentperspectivesonhypergastrinaemiaandenterochromaffinlikecellhyperplasia |
| mega_collection | Wiley (CrossRef) |
| physical | 5-10 |
| publishDate | 1999 |
| publishDateSort | 1999 |
| publisher | Wiley |
| record_format | ai |
| recordtype | ai |
| series | Alimentary Pharmacology & Therapeutics |
| source_id | 49 |
| spelling | Robinson 0269-2813 1365-2036 Wiley Pharmacology (medical) Gastroenterology Hepatology http://dx.doi.org/10.1046/j.1365-2036.1999.00033.x <jats:p>Rabeprazole, a new benzimidazole proton pump inhibitor (PPI), is among a class of agents known to be very potent inhibitors of gastric acid secretion. PPIs inhibit hydrogen‐potassium adenosine triphosphatase activity on the luminal surface of the parietal cell, effectively blocking the final common pathway for gastric acid secretion. Raising gastric pH stimulates the production of gastrin by G cells in the antrum of the stomach, which can lead to enterochromaffin‐like (ECL)‐cell hyperplasia. In the past, these changes have been viewed with concern, particularly in the light of studies in rats indicating that hypergastrinaemia and ECL‐cell hyperplasia induce gastric carcinoid tumour formation. All available clinical data indicate that long‐term PPI use does not lead to carcinoid tumour formation in humans. In fact, both serum gastrin elevation and ECL‐cell hyperplasia are now generally viewed as normal physiological responses to gastric acid suppression. Serum gastrin concentrations, in particular, correlate well with gastric acid suppression, which has led to the use of gastrin response by some investigators as a surrogate marker of antisecretory effectiveness. Long‐term tolerability data indicate that PPIs have a favourable side‐effect profile. Data obtained from patients receiving acute or long‐term maintenance rabeprazole therapy support this conclusion. Furthermore, neither animal nor human data obtained with rabeprazole suggest a significant risk for neoplastic changes secondary to hypergastrinaemia.</jats:p> Review article: current perspectives on hypergastrinaemia and enterochromaffin‐like‐cell hyperplasia Alimentary Pharmacology & Therapeutics |
| spellingShingle | Robinson, Alimentary Pharmacology & Therapeutics, Review article: current perspectives on hypergastrinaemia and enterochromaffin‐like‐cell hyperplasia, Pharmacology (medical), Gastroenterology, Hepatology |
| title | Review article: current perspectives on hypergastrinaemia and enterochromaffin‐like‐cell hyperplasia |
| title_full | Review article: current perspectives on hypergastrinaemia and enterochromaffin‐like‐cell hyperplasia |
| title_fullStr | Review article: current perspectives on hypergastrinaemia and enterochromaffin‐like‐cell hyperplasia |
| title_full_unstemmed | Review article: current perspectives on hypergastrinaemia and enterochromaffin‐like‐cell hyperplasia |
| title_short | Review article: current perspectives on hypergastrinaemia and enterochromaffin‐like‐cell hyperplasia |
| title_sort | review article: current perspectives on hypergastrinaemia and enterochromaffin‐like‐cell hyperplasia |
| title_unstemmed | Review article: current perspectives on hypergastrinaemia and enterochromaffin‐like‐cell hyperplasia |
| topic | Pharmacology (medical), Gastroenterology, Hepatology |
| url | http://dx.doi.org/10.1046/j.1365-2036.1999.00033.x |